



Patient Reported Outcomes

Improving Quality, Value, and Outcomes
with Patient-Reported Outcomes

Welcome



Tricia Lee Wilkins
Director, Pharmacy Affairs
Academy of Managed Care Pharmacy

Disclaimer

Organizations may not re-use material presented at this AMCP webinar for commercial purposes without the written consent of the presenter, the person or organization holding copyright to the material (if applicable), and AMCP. Commercial purposes include but are not limited to symposia, educational programs, and other forms of presentation, whether developed or offered by for-profit or not-for-profit entities, and that involve funding from for-profit firms or a registration fee that is other than nominal. In addition, organizations may not widely redistribute or re-use this webinar material without the written consent of the presenter, the person or organization holding copyright to the material (if applicable), and AMCP. This includes large quantity redistribution of the material or storage of the material on electronic systems for other than personal use.

A presentation slide with a blue background and a blurred image of a person presenting to an audience. The title is in yellow and white text. The description is in white text.

AMCP Partnership Forums Collaboration for Optimization

The live, hands-on AMCP Partnership Forums bring key decision-makers in managed care, integrated care, the pharmaceutical industry, and others together to discuss and collaborate on tactics and strategies to drive efficiencies and outcomes in integrated care and managed care.

A presentation slide with a blue and yellow geometric design on the left. The title is in black text. Below it are five horizontal bars with alternating yellow and light blue backgrounds, each containing a bullet point in black text.

Partnership Forums...

- Proactive, collaborative approach to solving key health care issues
- Provide a voice to all stakeholders
- Gain consensus on tactics to address challenges and opportunities
- Work together on common goals and interests
- High visibility among industry and policy stakeholders

©2018 AMCP Partnership Forums 4

2017 Partnership Forums

Advancing Value-Based Contracting

Patient Reported Outcomes

Driving Value and Outcomes in Oncology

Managing Care in the Wave of Precision Medicine



5

PRO Sponsors

AMGEN

 **Boehringer
Ingelheim**

Genentech
A Member of the Roche Group

gsk

 **NOVARTIS**
PHARMACEUTICALS

 **novo nordisk**

 **PRECISION[™]
FOR VALUE**

 **PREMIER**
TRANSFORMING
HEALTHCARE TOGETHER[™]

 **Allergan**
 **SANOFI**

 **Takeda**

 **Xcenda**
AmerisourceBergen



©2018 AMCP Partnership Forums

6

Our Faculty



Sheila Thomas
Sr. Director, Global Health
Economics and Value
Assessment, Sanofi



Lisa Opiari-Arrigan
Associate Professor,
Cincinnati Children's
Medical Center



Kellie Meyer
Senior Director,
Global Health Economics
and Outcomes Research
Xcenda, Amerisource
Bergen



©2018 AMCP Partnership Forums

7

Agenda



Why Patient Reported Outcomes Forum?



Forum Findings and Recommendations



Q&A




Next Steps and Action Items



8

How to Ask Questions



Why a PRO Partnership Forum?



Forum Participants

25+ participants from health plans, integrated delivery systems, pharmacy benefit managers, employers, data and analytics experts, biopharmaceutical companies and government agencies

Amgen	Novo Nordisk
Accelerated Cure Project for Multiple Sclerosis	OptumRx
Aetna	PCORI (Patient Centered Outcomes Research Institute)
Allergan	Pharmacy Quality Alliance
Boehringer Ingelheim Pharmaceuticals, Inc.	Precision For Value
Cincinnati Children's Hospital Medical Center	Premier
CMS	Regal Medical Group
FDA/CDER	Sanofi
Genentech	Takeda Pharmaceuticals
GlaxoSmithKline	The Ohio State University Health Plan, Inc.
Global Healthy Living Foundation (GHLF)	UPMC Health Plan
Healthagen	Vital Score
Inova Center for Personalized Health	Walgreens
National Quality Forum	Xcenda/AmerisourceBergen
Novartis Pharmaceuticals	



11

PROs Have a Number of Benefits

PROs are direct measures of patients' disease symptoms or characteristics that should be addressed and/or maintained

Understanding patient needs and preferences can promote better patient care

Allocate resources and define priorities
Develop better treatment plans & inform guideline development
Guide research to drive patient-centric care



©2018 AMCP Partnership Forums

12

Current Use of Pros

1. Assessing symptom severity
2. Informing treatment decisions
3. Determining patient preferences
4. Connecting clinicians to patient-generated data
5. Tracking outcomes
6. Prioritizing patient-clinician discussions
7. Monitoring general health and well-being
8. Evaluating population health initiatives

©2018 AMCP Partnership Forums 13

PRO Challenges

A clear and consistently defined methodology for developing, collecting, and using PROs

Engaging patients throughout the entire PRO process

Limited technology infrastructure



PRO Forum Goals

1. Determine how PROs are used in drug development and quality performance standards
2. Address obstacles that impact PRO utilization
3. Identify an ideal future state where PROs are used to maximize the goals of all healthcare stakeholders
4. Determine what actionable steps need to be taken to make an ideal future state reality

AMCP PARTNERSHIP FORUM

©2018 AMCP Partnership Forums 15

Consensus

1

PROs are crucial in defining value, improving patient care, and implementing value-based payment models.

2

Significant organizational and operational factors are needed to achieve adoption and use.

AMCP PARTNERSHIP FORUM

©2018 AMCP Partnership Forums 16

PRO Expansion Opportunities

Drug Development

Integration into clinical trial design and FDA drug and product labels

Clinical Care

Better align clinician and patient priorities

Formulary and coverage decision-making

Improve coverage decision-making and be used as a component of value-based contracting models



©2018 AMCP Partnership Forums

17

PRO Challenges

1 PRO Utilization in Drug Development and Quality Measures



©2018 AMCP Partnership Forums

18

Drug Development Challenges

Patient Populations

Often not representative of patients who use the treatments in real-world settings

Drug Labeling

Exploratory endpoints preventing making claims, such as comparisons across therapies

Continuous Data Collection

Requiring organizations to commit significant time and resources

Drug Development Recommendations

1. Broaden representative populations

2. Early alignment in drug development

3. Streamline data collection by engaging non-physician healthcare professionals

PRO Challenges

PRO Utilization in Patient Care



©2018 AMCP Partnership Forums 21

Clinical Utilization Challenges

PRO Data Collection and Analysis

Requires significant effort, so organizations must commit time and resources to use PROs

Standardization versus Custom PROs

Disease-specific PROs can better capture the continuum, but they often do not have the same validation



©2018 AMCP Partnership Forums 22

Clinical Utilization Challenges

Technology

Current collection methods can be time and resource intensive for both patients and clinicians

Predictive Analysis

PROs capture present and/or past patient data, but often not a patient's future health state or resource use

Utilization Recommendations

1. Better integration of PROs into EHRs
2. Ensure data is actionable
3. Data integrated into claims data
4. Common technology platforms (i.e. smart phones)
5. Greater emphasis on predictive design



Ideal Future State

AMCP PARTNERSHIP FORUM

©2018 AMCP Partnership Forums 25

Unique Priorities of Key PRO Stakeholders

Patients / Advocacy	Clinicians
<p>Simple, customizable PROs that reflect patient literacy and contextual factors</p> <p>Easy collection process</p> <p>Presented in a manner that is easily understood</p>	<p>Standard data collection and technology</p> <p>Incentives or goals to ensure collection of PROs</p> <p>PROs that can facilitate care decisions, streamline care, and align patient and clinician goals</p>

AMCP PARTNERSHIP FORUM

©2018 AMCP Partnership Forums 26

Unique Priorities of Key PRO Stakeholders

Payers

Prioritized PRO that were universally useful and relevant for all stakeholders

Used to make informed decision-making, resource utilization and developing care pathways

Integration into value-based contracting

Manufacturers

Widespread use in clinical trials to support the drug approval process

PROs must be scalable and representative broad patient population and useable in real-world settings

Data should be shared between manufacturers and clinicians to understand the impact of treatment in real-world settings



©2018 AMCP Partnership Forums 27

Future State

Development

- Patients incorporated at initial stages and throughout drug development
- PROs widely integrated into clinical trial designs
- Utilize PROs that have both a predictive and historical perspective

Validation

- Utilize common terminology
- Identify PROs that are simple and validated yet customizable
- Identify PROs that are clinically sensitive and medically relevant



©2018 AMCP Partnership Forums 28

Future State

Adoption & Use

- PRO collection that is streamlined and efficient throughout a patient's health or disease state
- Widespread integration of PRO endpoints into manufacturer labels

Analysis

- Identify a single platform for PRO collection and analysis
- Align clinician and payer incentives with PRO measurement and analysis
- Ensure PROs inform treatment decisions



©2018 AMCP Partnership Forums 29

Overarching Priorities to Achieve Future State

Common Framework or Terminology

Drive education
Inform best practices around care delivery and coverage determination

Meaningful Measures

Measures that have a ROI
Provide real-time insights to inform patient care or improve health

Technology and Infrastructure

EHR Integration
Better interoperability



©2018 AMCP Partnership Forums 30

Conclusions

PROs are important in fostering patient-centric care in drug development and creating care pathways

Barriers are limiting the greater use of PROs


Healthcare stakeholders must collaborate in developing best practices in drug development, clinical decision making and coverage decisions

Success contingent upon PROs that represent meaningful patient-driven measures

©2018 AMCP Partnership Forums

31

Reminder: How to Ask Questions During the Webinar



Next Steps



Proceedings

Published in JMCP March 2018 Issue

<https://www.jmcp.org/doi/abs/10.18553/jmcp.2018.17491>

Next Steps – 2018 Forums

Designing Benefits and Payment Models for Innovative High-Investment Medications, July 24-25, D.C

Managing Total Cost of Care Through Medical and Pharmacy Integration, Sept 25-26, D.C.

Building the Foundation for Patient Reported Outcomes: Infrastructure and Methodologies, October 25, Orlando

Integrated Delivery Network's Role in Value-Based Agreements for Pharmacy and Medical Benefits, Nov 13-14, D.C

Our Sponsors



Upcoming Webinars

www.amcp.org/calendar